| Characteristic | Description |
|---|---|
| Active Ingredient | Sildenafil Citrate |
| Dosage Forms | 20 mg tablets |
| Indications | Pulmonary Arterial Hypertension |
| Administration | Oral |
| Prescription Status | Prescription Only |
| More Information on Revatio | |
Chemical Structure
The active ingredient in Revatio is sildenafil citrate. Its chemical structure features a complex arrangement of nitrogen-containing rings. This compound falls under the class of PDE5 inhibitors. The crystalline form is white to off-white. Molecular formula C22H30N6O4S. Molecular weight: 474.58 g/mol.
When ingested, sildenafil acts by blocking the enzyme phosphodiesterase type 5 (PDE5). This leads to increased levels of cyclic guanosine monophosphate (cGMP). This cascade effect allows smooth muscle relaxation.
Through this mechanism, Revatio targets pulmonary arterial hypertension. It improves blood flow in the lungs. It reduces strain on the heart.
Areas of Use
Revatio is primarily indicated for pulmonary arterial hypertension (PAH). It serves patients with WHO Group I. By reducing blood pressure in the pulmonary arteries, it enhances exercise capacity.
Revatio’s role in treating PAH is significant. It alleviates symptoms such as shortness of breath and dizziness. The improvement in exercise capacity can significantly enhance life quality.
Sildenafil 20 mg can be administered orally. Physicians may adjust dosage based on the patient’s response. Regular monitoring ensures optimal therapeutic outcomes.
Warning & Precautions
Patients must adhere to prescribed doses. Overuse may result in adverse effects. Those with cardiovascular issues require close observation.
Consultation with healthcare providers is crucial. Especially for individuals with liver or kidney dysfunction. Certain medications may interact with Revatio. This includes nitrates and alpha-blockers.
Avoid sudden discontinuation of therapy. Gradual dose adjustment is advisable. This minimizes rebound effects and enhances safety.
Pregnancy and Breastfeeding
The use of Revatio during pregnancy requires caution. Insufficient data exists on its effects in pregnant women. Animal studies have not shown direct harm to the fetus.
During breastfeeding, it is not well established if sildenafil is excreted in human milk. Consultation with a healthcare provider is recommended. Weigh potential benefits against risks.
Toxicity
Sildenafil toxicity is rare but possible. Symptoms include severe hypotension and cardiovascular collapse. Prompt medical attention is essential.
Patients experiencing toxicity may require supportive measures. These include intravenous fluids and vasopressors. Monitoring and intervention should occur in a clinical setting.
Ensure accurate diagnosis and management. This involves awareness of the signs and careful medication history review.
Is Non-Prescription Revatio Available?
Revatio, unlike some formulations of sildenafil, remains prescription-only. This ensures appropriate medical oversight.
Access to Revatio requires consultation with a healthcare professional. It enables the safe and effective management of PAH.
Non-prescription availability of Revatio could lead to misuse. Prescription status supports patient safety and treatment efficacy.
